Medication treatment of different types of alcoholism

American Journal of Psychiatry

Volumn 167, Issue 6, 2010, Pages 630-639

  Johnson, Bankole A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ARIPIPRAZOLE; BACLOFEN; DISULFIRAM; NALTREXONE; ONDANSETRON; RIMONABANT; TOPIRAMATE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ALLELE; ANAMNESIS; BEHAVIOR THERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DISEASE PREDISPOSITION; DRINKING BEHAVIOR; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; EXCITEMENT; FAMILY HISTORY; HUMAN; HYPOTENSION; INSOMNIA; MESOLIMBIC DOPAMINERGIC SYSTEM; MOOD DISORDER; NAUSEA; NERVE TRACT; NEUROBIOLOGY; PATIENT MONITORING; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SOCIAL PSYCHOLOGY; SOMNOLENCE; URINARY FREQUENCY; VISUAL IMPAIRMENT;

ADULT; AGED; ALCOHOL DETERRENTS; ALCOHOLISM; BACLOFEN; CHRONIC DISEASE; DEPRESSIVE DISORDER; FEMALE; FRUCTOSE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LIMBIC SYSTEM; MALE; NALTREXONE; ONDANSETRON; PITUITARY-ADRENAL SYSTEM; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA; YOUNG ADULT;

EID: 77952987723     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2010.08101500     Document Type: Review

References (82)

1. US Department of Health and Human Services: 10th Special Report to the US Congress on Alcohol and Health. Bethesda, Md, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 2000
2. McLellan AT, Lewis DC, O'Brien CP, Kleber HD: Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284:1689-1695
3. Swift RM: Drug therapy for alcohol dependence. N Engl J Med 1999; 340:1482-1490
4. Finney JW, Hahn AC, Moos RH: The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 1996; 91:1773-1796 (Pubitemid 27032490)
5. Johnson BA, DiClemente CC, Ait-Daoud N, Stoks SM: Brief Behavioral Compliance Enhancement Treatment (BBCET) manual, in Handbook of Clinical Alcoholism Treatment. Edited by Johnson BA, Ruiz P, Galanter M. Baltimore, Lippincott Williams & Wilkins, 2003, pp 282-301
6. Pettinati HM, Weiss RD, Miller WR, Donovan D, Ernst DB, Rounsaville BJ: Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. COMBINE Monograph Series, vol 2 (DHHS Publication No. 04-5289). Bethesda, Md, National Institute on Alcohol Abuse and Alcoholism, 2004
7. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (COMBINE Study Research Group): Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295:2003-2017
8. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision. Washington, DC, American Psychiatric Association, 2000
9. Cloninger CR: Neurogenetic adaptive mechanisms in alcoholism. Science 1987; 236:410-416
10. Babor TF, Dolinsky ZS, Meyer RE, Hesselbrock M, Hofmann M, Tennen H: Types of alcoholics: concurrent and predictive validity of some common classification schemes. Br J Addict 1992; 87:1415-1431
11. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rounsaville B: Types of alcoholics, I. evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 1992; 49:599-608
12. Schuckit MA, Tipp JE, Smith TL, Shapiro E, Hesselbrock VM, Bucholz KK, Reich T, Nurnberger JI Jr: An evaluation of type A and B alcoholics. Addiction 1995;90:1189-1203
13. Miller WR, Marlatt GA: Manual for the Comprehensive Drinker Profile. Odessa, Fla, Psychological Assessment Resources, 1984
14. Johnson BA: Serotonergic agents and alcoholism treatment: rebirth of the subtype concept: an hypothesis. Alcohol Clin Exp Res 2000; 24:1597-1601
15. Lesch OM, Dietzel M, Musalek M, Walter H, Zeiler K: The course of alcoholism: long-term prognosis in different types. Forensic Sci Int 1988; 36:121-138 (Pubitemid 18007491)
16. Lesch OM, Walter H: Subtypes of alcoholism and their role in therapy. Alcohol Alcohol Suppl 1996; 1:63-67
17. Johnston LD, O'Malley PM, Bachman JG: Monitoring the Future National Survey Results on Drug Use, 1975-2002, vol 2, College Students and Adults Ages 19-40. Bethesda, Md, National Institute on Drug Abuse, 2003
18. Clapp JD, Lange JE, Russell C, Shillington A, Voas RB: A failed norms social marketing campaign. J Stud Alcohol 2003; 64:409-414 (Pubitemid 36629021)
19. Wechsler H, Lee JE, Kuo M, Seibring M, Nelson TF, Lee H: Trends in college binge drinking during a period of increased prevention efforts: findings from 4 Harvard School of Public Health College Alcohol Study surveys: 1993-2001. J Am Coll Health 2002; 50:203-217
20. Hingson RW, Heeren T, Zakocs RC, Kopstein A, Wechsler H: Magnitude of alcohol-related mortality and morbidity among U.S. college students ages 18-24. J Stud Alcohol 2002; 63:136-144 (Pubitemid 34533589)
21. Hingson R, Heeren T, Winter M, Wechsler H: Magnitude of alcohol-related mortality and morbidity among U.S. college students ages 18-24: changes from 1998 to 2001. Annu Rev Public Health 2005; 26:259-279
22. Fleming MF, Barry KL, MacDonald R: The Alcohol Use Disorders Identification Test (AUDIT) in a college sample. Int J Addict 1991; 26:1173-1185
23. Kypri K, Langley JD, McGee R, Saunders JB, Williams S: High prevalence, persistent hazardous drinking among New Zealand tertiary students. Alcohol Alcohol 2002; 37:457-464
24. Bruner AB, Fishman M: Adolescents and illicit drug use. JAMA 1998; 280:597-598
25. Apostolopoulos Y, Sönmez S, Yu CH: HIV-risk behaviours of American spring break vacationers: a case of situational disinhibition? Int J STD AIDS 2002; 13:733-743
26. Engs RC, Diebold BA, Hanson DJ: The drinking patterns and problems of a national sample of college students, 1994. J Alcohol Drug Educ 1996; 41:13-33
27. Presley CA, Meilman PW, Cashin JR: Alcohol and Drugs on American College Campuses: Use, Consequences, and Perceptions of the Campus Environment, vol 4, 1992-1994. Carbondale, Southern Illinois University, Core Institute, 1996
28. Presley CA, Pimentel ER: The introduction of the heavy and frequent drinker: a proposed classification to increase accuracy of alcohol assessments in postsecondary educational settings. J Stud Alcohol 2006; 67:324-331
29. Muthén B, Shedden K: Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 1999; 55:463-469 (Pubitemid 29302570)
30. Hill KG, White HR, Chung IJ, Hawkins JD, Catalano RF: Early adult outcomes of adolescent binge drinking: person- and variable-centered analyses of binge drinking trajectories. Alcohol Clin Exp Res 2000; 24:892-901
31. Dawson DA, Grant BF, Stinson FS, Chou PS: Another look at heavy episodic drinking and alcohol use disorders among college and noncollege youth. J Stud Alcohol 2004; 65:477-488
32. Slutske WS: Alcohol use disorders among US college students and their non-college-attending peers. Arch Gen Psychiatry 2005; 62:321-327
33. Knight JR, Wechsler H, Kuo M, Seibring M, Weitzman ER, Schuckit MA: Alcohol abuse and dependence among U.S. college students. J Stud Alcohol 2002; 63:263-270
34. Martin CS, Kaczynski NA, Maisto SA, Bukstein OM, Moss HB: Patterns of DSM-IV alcohol abuse and dependence symptoms in adolescent drinkers. J Stud Alcohol 1995; 56:672-680
35. Jennison KM: The short-term effects and unintended long-term consequences of binge drinking in college: a 10-year follow-up study. Am J Drug Alcohol Abuse 2004; 30:659-684
36. O'Neill SE, Parra GR, Sher KJ: Clinical relevance of heavy drinking during the college years: cross-sectional and prospective perspectives. Psychol Addict Behav 2001; 15:350-359
37. Grant BF, Kaplan K, Shepard J, Moore T: Source and Accuracy Statement for Wave 1 of the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions. Bethesda, Md, National Institute on Alcohol Abuse and Alcoholism, 2003
38. Hasin DS, Goodwin RD, Stinson FS, Grant BF: Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005; 62:1097-1106
39. Lynskey MT: The comorbidity of alcohol dependence and affective disorders: treatment implications. Drug Alcohol Depend 1998; 52:201-209
40. Wang J, El-Guebaly N: Sociodemographic factors associated with comorbid major depressive episodes and alcohol dependence in the general population. Can J Psychiatry 2004; 49:37-44
41. McEachin RC, Keller BJ, Saunders EF, McInnis MG: Modeling gene-by-environment interaction in comorbid depression with alcohol use disorders via an integrated bioinformatics approach. BioData Min 2008; 1:2
42. Blow FC, Barry KL: Use and misuse of alcohol among older women. Alcohol Res Health 2002; 26:308-315
43. Merikangas KR, Gelernter CS: Comorbidity for alcoholism and depression. Psychiatr Clin North Am 1990; 13:613-632
44. Thase ME, Salloum IM, Cornelius JD: Comorbid alcoholism and depression: treatment issues. J Clin Psychiatry 2001; 62(suppl 20):32-41 (Pubitemid 32917097)
45. Hemby SE, Johnson BA, Dworkin SI: Neurobiological basis of drug reinforcement, in Drug Addiction and Its Treatment: Nexus of Neuroscience and Behavior. Edited by Johnson BA, Roache JD. Philadelphia, Lippincott-Raven, 1997, pp 137-169
46. Johnson BA: New weapon to curb smoking: no more excuses to delay treatment. Arch Intern Med 2006; 166:1547-1550
47. Johnson BA: Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008; 75:34-56
48. Koob GF, Le Moal M: Plasticity of reward neurocircuitry and the "dark side" of drug addiction. Nat Neurosci 2005; 8:1442-1444
49. National Institute on Alcohol Abuse and Alcoholism: Helping Patients Who Drink Too Much: A Clinician's Guide: Updated 2005 Edition (NIH Publication No. 07-3769). Bethesda, Md, US Department of Health and Human Services, 2005
50. Reinert DF, Allen JP: The Alcohol Use Disorders Identification Test (AUDIT): a review of recent research. Alcohol Clin Exp Res 2002; 26:272-279
51. Miller WR, Heather N, Hall W: Calculating standard drink units: international comparisons. Br J Addict 1991; 86:43-47
52. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE: An over-view of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41(suppl 1):S3-S9
53. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ: Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361:1677-1685 (Pubitemid 36577440)
54. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM (Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group): Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298:1641-1651
55. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000; 41(suppl 1):S17-S20
56. Johnson BA: Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 2005; 19:873-896
57. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Addolorato G, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM (Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group): Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment. Arch Intern Med 2008; 168:1188-1199
58. Cruz HG, Ivanova T, Lunn ML, Stoffel M, Slesinger PA, Lüscher C: Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat Neurosci 2004; 7:153-159 (Pubitemid 38129791)
59. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G: Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370:1915-1922
60. Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G: Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 2006; 119:276.e13-276.e18
61. Alpha Pharmaceuticals: Alpha-baclofen: data sheet. http:// www.medsafe.govt.nz/profs/datasheet/a/alphabaclofentab.htm
62. Blazer DG, Wu L-T: The epidemiology of at-risk and binge drinking among middle-aged and elderly community adults: National Survey on Drug Use and Health. Am J Psychiatry 2009; 166:1162-1169
63. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, Thase ME, Black A: Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54:700-705 (Pubitemid 27344096)
64. Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O'Malley SS: Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry 2007; 62:694-697 (Pubitemid 47314376)
65. Ait-Daoud N, Malcolm RJ Jr, Johnson BA: An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addict Behav 2006; 31:1628-1649 (Pubitemid 44142844)
66. Dimeff LA, Baer JS, Kivlahan DR, Marlatt GA: Brief Alcohol Screening and Intervention for College Students (BASICS): A Harm Reduction Approach. New York, Guilford, 1999
67. Baer JS, Kivlahan DR, Blume AW, McKnight P, Marlatt GA: Brief intervention for heavy-drinking college students: a 4-year follow- up and natural history. Am J Public Health 2001; 91:1310-1316 (Pubitemid 32708875)
68. Ait-Daoud N, Johnson BA: Medications for the treatment of alcoholism, in Handbook of Clinical Alcoholism Treatment. Edited by Johnson BA, Ruiz P, Galanter M. Baltimore, Lippincott Williams & Wilkins, 2003, pp 119-130
69. Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, Fu MC, Hart SR, Pedigo NW, Littleton JM: Acamprosate inhibits the binding and neurotoxic effects of trans- ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002; 26:1779-1793
70. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M: Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 2008; 319:1536-1539
71. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA: A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 2008; 32:1429-1438
72. Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J: A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 2008; 28:5-12
73. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Wiedemann K: Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60:92-99
74. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP: A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28:1546-1552 (Pubitemid 41070891)
75. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D: An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008; 65:135-144
76. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH (VA Cooperative Study #425 Study Group): Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 2007; 31:555-563
77. Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto T, Mäkelä R, Kranzler HR: Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res 2008; 32:1159-1166
78. Lesch KP, Greenberg BD, Higley JD: Serotonin transporter, personality, and behavior: toward dissection of gene-gene and gene-environment interaction, in Molecular Genetics and the Human Personality. Edited by Benjamin J, Ebstein RP, Belmaker RH. Washington, DC, American Psychiatric Publishing, Inc, 2002, pp 109-136
79. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66:2621-2624
80. Heils A, Mossner R, Lesch KP: The human serotonin transporter gene polymorphism: basic research and clinical implications. J Neural Transm 1997; 104:1005-1014
81. Ait-Daoud N, Roache JD, Dawes MA, Liu L, Wang X-Q, Javors MA, Seneviratne C, Johnson BA: Can serotonin transporter genotype predict craving in alcoholism? Alcohol Clin Exp Res 2009; 33:1329-1335
82. Kenna GA, Zywiak WH, McGeary JE, Leggio L, McGeary C, Wang S, Grenga A, Swift RM: A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res 2009; 33:315-323